Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis - KIVIRID

Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

Authors: Jessica A. Huthmacher, Juris J. Meier, Michael A. Nauck

Published: 2020-08-20

DOI: 10.2337/dc20-0498

Source: Full article

Abstract

PURPOSE